What is CoapTech?
CoapTech is a medical technology firm focused on the development and commercialization of the PUMA (Point-of-care Ultrasound Magnet Aligned) System. This platform represents a significant advancement in medical imaging, enabling the utilization of ultrasound within hollow organ cavities. By facilitating minimally invasive, bedside procedures, the PUMA System is designed to enhance patient safety, improve clinical outcomes, and substantially reduce healthcare costs. The company's flagship application, PUMA-G, has already achieved critical regulatory milestones, including FDA 510(k) clearance and a CE mark, validating its utility for ultrasound gastrostomy in adult patients. Recognized as a Medtech Innovator Best-in-Class startup, CoapTech is effectively bridging the gap between complex surgical requirements and point-of-care accessibility.
How much funding has CoapTech raised?
CoapTech has raised a total of $12.9M across 5 funding rounds:
Angel/Seed
$2.4M
Series A
$3.2M
Debt
$150K
Series B
$7M
Debt
$203K
Angel/Seed (2018): $2.4M with participation from Maryland Technology Development, UM Venture, and National Institutes of Health
Series A (2019): $3.2M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Series B (2020): $7M, investors not publicly disclosed
Debt (2021): $203K backed by PPP
Key Investors in CoapTech
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical support for medical innovation.
Maryland Technology Development
A state-backed organization focused on fostering economic growth by investing in technology-based companies and startups within the Maryland region.
UM Venture
A venture capital entity dedicated to commercializing research and intellectual property originating from the University of Maryland system.
What's next for CoapTech?
With the support of its latest capital injection, CoapTech is poised to transition into a broader commercial rollout of its PUMA platform. The strategic focus will likely center on expanding the clinical indications for the PUMA System and deepening market penetration within the U.S. and international healthcare systems. As the company moves beyond its initial regulatory successes, the management team is expected to prioritize operational scaling and the establishment of new clinical partnerships. By leveraging its unique magnet-aligned ultrasound technology, CoapTech is well-positioned to disrupt traditional surgical workflows, potentially setting a new standard for bedside medical interventions and long-term patient care management.
See full CoapTech company page
